Ulisse Biomed launches a new phase of growth

“The half-year results clearly show that a significant phase of the company has come to an end. The approximately 40% growth in sales revenue is proof that this transition has now been completed,” stated Nicola Basile, Chief Executive Officer of Ulisse Biomed, to Teleborsa during the sixth edition of NextGems, the investor conference focused on small-cap companies listed on Borsa Italiana.

Regarding the investment signed with Global Corporate Finance and Sterling Atlantic, the executive highlighted: “The transaction involves a commitment of up to €10 million over three years from the U.S. companies. It is a minimally dilutive investment and is primarily aimed at financing initiatives in the three areas we plan to develop over the next three years: continued vertical integration of our business; international expansion; and the evaluation of potential corporate transactions that could accelerate growth, always with the ultimate goal of providing our clients with a comprehensive and vertically integrated offering.”

 Ulisse is expanding its scope by entering high-value technological markets and sectors with strong growth and significant potential. In particular, the focus is on the so-called Next Generation Sequencing (NGS) market. “We are entering a new phase in the life of Ulisse Biomed because sequencing runs in parallel with our existing proprietary technology, which is PCR. This comes with two important aspects: first, the added value of this business is significantly higher than that of PCR; and second, it is an Italian and European market growing at a rate three to five times higher, depending on the market, than our current business”.